MaxCyte, Inc. — Q1 2023 Form 10-Q Summary
Business context and reporting period
MaxCyte is a life sciences company providing cell-engineering instruments, technology, consumables and related licenses for cell therapy, drug discovery, development and biomanufacturing. The filing covers the unaudited three months ended March 31, 2023, compared with the three months ended March 31, 2022.
Key financial metrics
| Metric | Q1 2023 | Q1 2022 | Change |
|---|---|---|---|
| Revenue | $8.6 million | $11.6 million | Down 26% |
| Gross profit | $7.6 million | $10.5 million | Down 28% |
| Gross margin | 88% | 91% | Down 3 percentage points |
| Operating loss | $13.2 million | $4.2 million | Loss increased |
| Net loss | $10.9 million | $4.1 million | Loss increased |
| Net loss per share | $0.11 | $0.04 | Loss increased |
| Cash used in operating activities | $4.3 million | $3.7 million | Use increased |
- Revenue comprised $6.0 million from cell therapy, $1.8 million from drug discovery and $0.8 million from program-related revenue.
- Operating expenses were $20.8 million, including research and development of $6.0 million, sales and marketing of $6.3 million, general and administrative expense of $7.5 million, and depreciation and amortization of $0.9 million.
- Interest income increased to $2.3 million from $0.1 million, reflecting higher interest rates and invested cash balances.
- Cash and cash equivalents were $37.8 million, and short-term investments were $186.8 million, totaling $224.7 million in liquidity at March 31, 2023.
- The company had no debt obligations. Operating lease liabilities totaled $16.3 million, with approximately $29.6 million of incremental non-cancellable lease payments under the new headquarters lease.
- Total assets were $281.5 million and stockholders’ equity was $247.8 million at March 31, 2023.
Material changes versus the prior comparable period
- Revenue declined $3.0 million, primarily because cell therapy revenue decreased 19%, drug discovery revenue decreased 17%, and program-related revenue decreased 60%.
- Cell therapy revenue was affected by lower instrument and disposable sales, partly due to customer purchase timing. Program-related revenue remains volatile because it depends on a limited number of milestone events.
- Gross margin declined from 91% to 88%, primarily due to revenue mix and initial lower utilization costs from scaling in-house manufacturing of processing assemblies.
- Research and development expense increased 61%, sales and marketing expense increased 64%, and general and administrative expense increased 13%, reflecting higher headcount, compensation, commercialization activity, product development and consulting costs.
- Net cash used in operating activities increased to $4.3 million. Investing activities provided $29.6 million, primarily from $89.0 million of investment maturities partially offset by $57.8 million of investment purchases and $1.6 million of capital expenditures.
- Common shares outstanding increased to 102.9 million at March 31, 2023 from 102.4 million at December 31, 2022, primarily from stock-option exercises.
- Stock-based compensation increased to $3.3 million from $2.5 million; $33.1 million of unrecognized compensation expense remained at quarter-end.
Guidance, outlook, commentary, risks and unusual items
- Management expects continued revenue growth over time as customer programs advance, markets expand, the installed base grows and additional strategic platform license agreements are signed. The filing does not provide specific numerical revenue or earnings guidance.
- Management expects near-term operating losses and continued increases in research and development, sales and marketing, and general and administrative expenses.
- Management states that existing cash and short-term investments should fund operating and capital requirements for the foreseeable future, but notes that actual cash usage could exceed expectations and additional equity or debt financing may become necessary.
- MaxCyte signed an SPL agreement with Catamaran Bio during the quarter and expects additional agreements, although timing is uncertain.
- Phase 3 of the new headquarters lease is expected to begin in the second half of 2023. The lease term expires August 31, 2035.
- Key risks include dependence on customer and partner program progress, variability in milestone revenue, availability of capital to cell therapy customers, competition in non-viral delivery, regulatory and intellectual-property risks, execution of manufacturing scale-up, and continued operating losses.
- Two customers represented 23% and 11% of Q1 revenue; two customers represented 23% and 12% of accounts receivable at March 31, 2023. One supplier represented 60% of inventory purchases during the quarter.
- The company reported no material legal proceedings and no material changes to the risk factors in its 2022 Form 10-K. Disclosure controls were effective as of March 31, 2023.
- Douglas Swirsky became Chief Financial Officer on March 27, 2023; former interim CFO Ron Holtz remained Executive Vice President of Administration but ceased to be an executive officer upon filing of the report.
Important facts for investors to verify
- Whether the Q1 revenue decline reflects temporary customer purchasing timing or a sustained slowdown in instrument, disposable and cell-therapy demand.
- The timing, size and probability of future SPL milestone and commercialization payments.
- Progress and utilization levels in the company’s in-house manufacturing operations and the resulting effect on gross margin.
- Operating cash-burn trends relative to the $224.7 million cash and short-term investment balance.
- Customer and supplier concentration, including the effects of any lost customer, delayed program or supply disruption.
- Execution of the headquarters expansion and the company’s approximately $29.6 million of remaining non-cancellable lease payments.
- The effect of increasing operating expenses and stock-based compensation on the path to profitability and future share dilution.